ID :
51083
Wed, 03/18/2009 - 10:01
Auther :
Shortlink :
https://www.oananews.org//node/51083
The shortlink copeid
STATE PHARMACEUTICAL COMPANIES AIMS TO CONTROL 15 PCT MARKET SHARE
Jakarta, March 17 (ANTARA) - Two state-owned pharmaceutical companies PT Kimia Farma Tbk and PT Indofarma Tbk were hoping to increase their market share to 15 percent after they formed a merger.
"The figure is not yet final but it is expected it could reach 17 percent," Kimia Farma's president director Syamsul Arifin said after exposing the merger plan of the two companies here on Tuesday.
He said confirmation on the target of market share still had yet to wait for the result of an analysis by PT Mandiri Sekuritas as financial advisor for the merger.
The office of the state enterprises minister representing the shareholders had agreed to the planned establishment of a state-owned pharmaceutical holding company which was expected to be operational in 2010.
The merger of the two companies that have an almost similar line of business is meant for increasing focus and competitiveness to meet similar companies from abroad who were entering the country.
"Efficiency will increase to boost income and profit margin," he said.
Sharing the view, the president director of Indofarma, P Sudibyo, said his side still waited the result of calculation by PT Mandiri Sekuritas with regard to the value of the company including assets from the merger.
He admitted some of the two companies' businesses were overlapping so that they needed reordering.
For that, he said, the new company later would focus on developing four produciton lines from downstream to upstream.
He said the new company planned to develop production of medicines in the chemical sector, increase capacity in the pharmaceutical sector, health equipment and export-import in the production sector and in the distribution sector to increase trade and develop drug store network across the country and a center of sales of pharmaceutial and healthcare products.
Sudibyo said Kimia Farma's line of business covers chamicals the production of which could be maximized to reduce supply of imported raw materials.
"The figure is not yet final but it is expected it could reach 17 percent," Kimia Farma's president director Syamsul Arifin said after exposing the merger plan of the two companies here on Tuesday.
He said confirmation on the target of market share still had yet to wait for the result of an analysis by PT Mandiri Sekuritas as financial advisor for the merger.
The office of the state enterprises minister representing the shareholders had agreed to the planned establishment of a state-owned pharmaceutical holding company which was expected to be operational in 2010.
The merger of the two companies that have an almost similar line of business is meant for increasing focus and competitiveness to meet similar companies from abroad who were entering the country.
"Efficiency will increase to boost income and profit margin," he said.
Sharing the view, the president director of Indofarma, P Sudibyo, said his side still waited the result of calculation by PT Mandiri Sekuritas with regard to the value of the company including assets from the merger.
He admitted some of the two companies' businesses were overlapping so that they needed reordering.
For that, he said, the new company later would focus on developing four produciton lines from downstream to upstream.
He said the new company planned to develop production of medicines in the chemical sector, increase capacity in the pharmaceutical sector, health equipment and export-import in the production sector and in the distribution sector to increase trade and develop drug store network across the country and a center of sales of pharmaceutial and healthcare products.
Sudibyo said Kimia Farma's line of business covers chamicals the production of which could be maximized to reduce supply of imported raw materials.
